Virtu Financial LLC Makes New $83,000 Investment in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Virtu Financial LLC purchased a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 15,694 shares of the company’s stock, valued at approximately $83,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Samlyn Capital LLC lifted its holdings in Corvus Pharmaceuticals by 160.7% during the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after acquiring an additional 3,774,658 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Corvus Pharmaceuticals during the second quarter worth about $10,855,000. Geode Capital Management LLC lifted its holdings in shares of Corvus Pharmaceuticals by 22.4% during the 3rd quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock valued at $2,974,000 after purchasing an additional 102,869 shares in the last quarter. Towerview LLC grew its position in shares of Corvus Pharmaceuticals by 4.6% in the 2nd quarter. Towerview LLC now owns 400,000 shares of the company’s stock valued at $728,000 after purchasing an additional 17,500 shares during the period. Finally, State Street Corp increased its stake in Corvus Pharmaceuticals by 48.2% during the 3rd quarter. State Street Corp now owns 178,246 shares of the company’s stock worth $941,000 after purchasing an additional 57,943 shares in the last quarter. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Stock Up 8.3 %

Shares of CRVS stock opened at $5.09 on Friday. Corvus Pharmaceuticals, Inc. has a 12 month low of $1.30 and a 12 month high of $10.00. The company’s fifty day simple moving average is $8.14 and its 200-day simple moving average is $5.05. The firm has a market cap of $327.07 million, a PE ratio of -5.47 and a beta of 1.05.

Wall Street Analysts Forecast Growth

CRVS has been the topic of a number of research reports. Mizuho raised shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. Oppenheimer boosted their price objective on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. LADENBURG THALM/SH SH upped their target price on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Finally, StockNews.com downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Corvus Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $12.83.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.